000294547 001__ 294547
000294547 005__ 20250130145226.0
000294547 0247_ $$2doi$$a10.1038/s41568-024-00769-5
000294547 0247_ $$2pmid$$apmid:39548283
000294547 0247_ $$2ISSN$$a1474-175X
000294547 0247_ $$2ISSN$$a1474-1768
000294547 0247_ $$2altmetric$$aaltmetric:170433295
000294547 037__ $$aDKFZ-2024-02322
000294547 041__ $$aEnglish
000294547 082__ $$a610
000294547 1001_ $$0P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079$$aSimovic-Lorenz, Milena$$b0$$eFirst author$$udkfz
000294547 245__ $$aChromothripsis in cancer.
000294547 260__ $$aLondon [u.a.]$$bNature Publ. Group$$c2025
000294547 3367_ $$2DRIVER$$aarticle
000294547 3367_ $$2DataCite$$aOutput Types/Journal article
000294547 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1738245117_14628$$xReview Article
000294547 3367_ $$2BibTeX$$aARTICLE
000294547 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000294547 3367_ $$00$$2EndNote$$aJournal Article
000294547 500__ $$a#EA:B420#LA:B420# / Volume 25 | February 2025 | 79–92
000294547 520__ $$aChromothripsis is a mutational phenomenon in which a single catastrophic event generates extensive rearrangements of one or a few chromosomes. This extreme form of genome instability has been detected in 30-50% of cancers. Studies conducted in the past few years have uncovered insights into how chromothripsis arises and deciphered some of the cellular and molecular consequences of chromosome shattering. This Review discusses the defining features of chromothripsis and describes its prevalence across different cancer types as indicated by the manifestations of chromothripsis detected in human cancer samples. The different mechanistic models of chromothripsis, derived from in vitro systems that enable causal inference through experimental manipulation, are discussed in detail. The contribution of chromothripsis to cancer development, the selective advantages that cancer cells might gain from chromothripsis, the evolutionary trajectories of chromothriptic tumours, and the potential vulnerabilities and therapeutic opportunities presented by chromothriptic cells are also highlighted.
000294547 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000294547 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000294547 7001_ $$0P:(DE-He78)509fb81813c1911954da583129e8ea57$$aErnst, Aurélie$$b1$$eLast author$$udkfz
000294547 773__ $$0PERI:(DE-600)2060549-3$$a10.1038/s41568-024-00769-5$$n2$$p79–92$$tNature reviews / Cancer$$v25$$x1474-175X$$y2025
000294547 909CO $$ooai:inrepo02.dkfz.de:294547$$pVDB
000294547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1fdaffee272e57a73f861a0ea36c4079$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000294547 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)509fb81813c1911954da583129e8ea57$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000294547 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000294547 9141_ $$y2024
000294547 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-08-26$$wger
000294547 915__ $$0StatID:(DE-HGF)3003$$2StatID$$aDEAL Nature$$d2023-08-26$$wger
000294547 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV CANCER : 2022$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)1120$$2StatID$$aDBCoverage$$bBIOSIS Reviews Reports And Meetings$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-26
000294547 915__ $$0StatID:(DE-HGF)9970$$2StatID$$aIF >= 70$$bNAT REV CANCER : 2022$$d2023-08-26
000294547 9202_ $$0I:(DE-He78)B420-20160331$$kB420$$lGenominstabilität in Tumoren$$x0
000294547 9201_ $$0I:(DE-He78)B420-20160331$$kB420$$lGenominstabilität in Tumoren$$x0
000294547 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x1
000294547 9200_ $$0I:(DE-He78)B420-20160331$$kB420$$lGenominstabilität in Tumoren$$x0
000294547 980__ $$ajournal
000294547 980__ $$aVDB
000294547 980__ $$aI:(DE-He78)B420-20160331
000294547 980__ $$aI:(DE-He78)HD01-20160331
000294547 980__ $$aUNRESTRICTED